...
首页> 外文期刊>Pakistan journal of medical sciences. >The relationship of visfatin with measures of obesity in patients of diabetic nephropathy
【24h】

The relationship of visfatin with measures of obesity in patients of diabetic nephropathy

机译:类糖尿病肾病患者肥胖措施的关系

获取原文

摘要

Objective: Visfatin is proposed as an adipocytokine secreted from visceral fat and its blood level correlate with obesity, diabetes mellitus and inflammation. Aim of this study was to examine association of serum visfatin with measures of obesity in a group of patients with diabetic nephropathy and normal controls. Methodology: This was a cross sectional study analyzing 60 subjects including 30 patients of diabetic nephropathy and 30 controls. Anthropometric measurements were done using standard methods and visfatin was measured through EIA Kit. Results: Serum visfatin in obese subjects among both groups was not different from non obese subjects (7.9 ?6.1 vs. 6.4 ? 3.2 p=0.238). We found a positive correlation of visfatin with BMI (r=0.313, p Conclusion: Serum visfatin does not correlate with markers of visceral obesity including waist circumference and waist to hip ratio. However, a positive correlation is observed with BMI. Future studies involving larger sample size and quantifying visceral tissue expression of visfatin may explain its potential role in visceral obesity.
机译:目的:取决于从内脏脂肪和血液水平与肥胖,糖尿病和炎症相关的脂肪蛋白。本研究的目的是在一组糖尿病肾病和正常对照的一组患者中检查血清类缺失的血清类毒素的关联。方法论:这是一个横断面研究分析60项受试者,包括30名糖尿病肾病和30例对照。使用标准方法进行人体测量测量,并通过EIA试剂盒测量缺失。结果:两组肥胖受试者的血清类酵母与非肥胖受试者不同(7.9?6.1与6.4?3.2 p = 0.238)。我们发现Visuatin与BMI的正相关(R = 0.313,P结论:血清Visfatin与内心肥胖的标记不相关,包括腰围和腰部臀部比率。然而,用BMI观察到阳性相关性。未来的研究涉及更大的研究样品尺寸和量化Visfatin的内脏组织表达可以解释其在内脏肥胖症中的潜在作用。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号